167 related articles for article (PubMed ID: 22218251)
21. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
22. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
23. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Kim H; Lee SC; Kwon KY; Lee JH; Koh HJ; Byeon SH; Kim SS; Kim M; Lee CS
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1497-1503. PubMed ID: 26626772
[TBL] [Abstract][Full Text] [Related]
24. Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy.
Nishijima K; Takahashi M; Akita J; Katsuta H; Tanemura M; Aikawa H; Mandai M; Takagi H; Kiryu J; Honda Y
Am J Ophthalmol; 2004 Apr; 137(4):770-3. PubMed ID: 15059729
[TBL] [Abstract][Full Text] [Related]
25. Optic disk melanocytoma associated with polypoidal choroidal vasculopathy lesions, after combination treatment of photodynamic therapy and intavitreal aflibercept (Eylea), a case report.
Rouvas A; Gouliopoulos NS; Moschos MM; Theodossiadis P
BMC Ophthalmol; 2018 Oct; 18(1):267. PubMed ID: 30309335
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic effects of bevacizumab in patients with polypoidal choroidal vasculopathy.
Lee SY; Kim JG; Joe SG; Chung H; Yoon YH
Korean J Ophthalmol; 2008 Jun; 22(2):92-9. PubMed ID: 18612226
[TBL] [Abstract][Full Text] [Related]
27. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.
Park S; Cho HJ; Lee DW; Kim CG; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1511-1517. PubMed ID: 26631136
[TBL] [Abstract][Full Text] [Related]
29. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Oct; 156(4):652-60. PubMed ID: 23891333
[TBL] [Abstract][Full Text] [Related]
30. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.
Pikkel J; Rumelt S
Eur J Ophthalmol; 2012; 22(3):488-91. PubMed ID: 21928270
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
33. Polypoidal Choroidal Vasculopathy with Feeder Vessels: Characteristics, Fellow Eye Findings, and Long-term Treatment Outcomes.
Hwang HJ; Kim JH; Chang YS; Kim JW; Kim CG
Korean J Ophthalmol; 2017 Jun; 31(3):230-239. PubMed ID: 28534339
[TBL] [Abstract][Full Text] [Related]
34. Current management strategy of polypoidal choroidal vasculopathy.
Ho CPS; Lai TYY
Indian J Ophthalmol; 2018 Dec; 66(12):1727-1735. PubMed ID: 30451173
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.
Nomura Y; Obata R; Yanagi Y
Jpn J Ophthalmol; 2012 May; 56(3):245-9. PubMed ID: 22526618
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
37. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
38. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW
Retina; 2013; 33(10):2126-32. PubMed ID: 23609123
[TBL] [Abstract][Full Text] [Related]
39. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
40. INTRAVITREAL AFLIBERCEPT IN THE TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY ASSOCIATED WITH MORNING GLORY SYNDROME.
Iovino C; Fossarello M; Peiretti E
Retin Cases Brief Rep; 2020; 14(3):278-281. PubMed ID: 29324624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
